Unit Dose Manufacturing Market Report 2025

The unit dose manufacturing market size has grown exponentially in recent years. It will grow from $32.82 billion in 2024 to $39.7 billion in 2025 at a compound annual growth rate (CAGR) of 21%. The growth in the historic period can be attributed to traditional pharmaceutical manufacturing practices, regulatory developments in drug packaging, rise in demand for personalized medicine, growth of the aging population, and increased prevalence of chronic diseases.

The unit dose manufacturing market size is expected to see exponential growth in the next few years. It will grow to $88.11 billion in 2029 at a compound annual growth rate (CAGR) of 22.1%. The growth in the forecast period can be attributed to the adoption of Industry 4 in pharmaceutical manufacturing, emphasis on personalized and precision medicine, regulatory focus on drug safety and efficacy, expansion of pharmaceutical outsourcing, and growing demand for patient-centric drug delivery. Major trends in the forecast period include the implementation of advanced automation in unit dose manufacturing, integration of IoT in pharmaceutical packaging, customization of unit dose packaging for specific drugs, adoption of sustainable and eco-friendly packaging materials, and growth of 3d printing in personalized drug manufacturing.

The increase in healthcare spending is expected to drive the growth of the unit dose manufacturing market in the future. Healthcare spending encompasses all costs related to providing health services, family planning activities, nutrition programs, and emergency health assistance. Rising healthcare expenditure will facilitate the advancement and development of various health-related services, including unit dose manufacturing, thereby supporting the growth of the unit dose manufacturing market. For instance, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, indicated that the U.S. pharmaceutical industry generated $550 billion in revenue. In 2021, Americans spent $576.9 billion on medicine, with projected spending expected to rise to between $605 billion and $635 billion by 2025. Therefore, the increase in healthcare spending is driving the growth of the unit dose manufacturing market.

The burgeoning demand for personalized medicine is poised to be a key driver of growth in the unit dose manufacturing market. Personalized medicine involves the use of knowledge about an individual's genes or proteins to prevent, detect, or treat diseases. Unit dose manufacturing plays a pivotal role in personalized medicine by providing a platform for producing individualized doses tailored to the specific needs of patients. As highlighted by the Personalized Medicine Coalition, approximately 34% of all newly approved therapeutic molecular entities in 2022 were personalized medicines, with 12 such medicines receiving approval from the US Food and Drug Administration (FDA). This surge in demand for personalized medicine is a significant factor propelling the expansion of the unit dose manufacturing market.

Product innovations are a significant trend gaining traction in the unit-dose manufacturing market. Key companies in this sector are developing new products to maintain their competitive edge. For example, in August 2024, Eli Lilly and Company, a US-based pharmaceutical firm, announced the availability of Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials for self-pay patients with an on-label prescription, thereby expanding access to meet growing demand. These vials are priced at a discount of 50% or more compared to the list prices of other incretin (GLP-1) obesity treatments. This new option provides affordable access to millions of adults with obesity, including those who are not eligible for the Zepbound savings card, those lacking employer-sponsored coverage, and those paying out-of-pocket without insurance.

Strategic partnerships are emerging as a prominent strategy adopted by major players to sustain and enhance their position in the unit dose manufacturing market. Strategic partnerships involve leveraging each other's strengths and resources to achieve mutual benefits and success. In November 2023, iA, a US-based provider of integrated pharmacy fulfillment platforms, announced a distributor agreement with Euclid Medical Products, a US-based specialist in multi-unit automated packaging and barcoding systems. This collaboration involves integrating Euclid’s Axial Adherence Packaging Technology into iA's NEXiA Enterprise Software Suite, expanding the capabilities of centralized fulfillment solutions. This partnership offers multiple medication dispensing methods, including multi- and unit-dose automated packaging, providing comprehensive solutions to meet diverse healthcare needs.

In August 2022, LTS Lohmann Therapie-Systeme AG, a Germany-based pharmaceutical technology company specializing in drug delivery systems, acquired Tapemark Inc. for an undisclosed amount. This acquisition positions LTS Lohmann Therapie-Systeme AG as a leading contract development and manufacturing organization for transdermal patches and oral thin films while expanding its footprint in the US. Tapemark Inc., based in the US, is a full-service contract development and manufacturing organization specializing in transdermal, oral thin film, and unit-dose products. The acquisition reflects a commitment to growth and diversification within the unit dose manufacturing sector.

Major companies operating in the unit dose manufacturing market include Nipro Corporation, Thermo Fisher Scientific Inc., Amcor plc, Berry Global, CCL Industries, Sealed Air Corporation, Huhtamäki Oyj, Catalent Inc., AptarGroup, Schott AG, West Pharmaceuticals Services Inc., Constantia Flexibles Group GmbH, Gerresheimer AG, RPC Group, Klöckner Pentaplast Group, Stevanato Group, Bemis Company, Corden Pharma GmbH, LTS Lohmann Therapie-Systeme AG, PCI Pharma Services, Comar LLC, Renaissance Lakewood LLC, Mikart LLC, Tapemark Company Inc., Bilcare Research, Medical Packaging Inc, American Health Packaging, Aphena Pharma Solutions.

North America was the largest region in the unit dose manufacturing market in 2024. The regions covered in the unit dose manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the unit dose manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Unit dosage manufacturing involves the production of individual pre-packaged doses of drugs or other products containing a specific quantity of medication intended for single-dose administration. These doses are typically presented in easily administered forms such as tablets, capsules, or vials, facilitating patient dispensing.

The primary products of unit dose manufacturing include liquid unit dose, solid unit dose, and others. A liquid unit dose specifically denotes a predetermined and customized amount of liquid medication or chemical enclosed in a single packaging unit, typically designed for single-use delivery. The sourcing methods for unit dose manufacturing include both in-house production and outsourcing, with utilization by various entities such as independent pharmacies, long-term care facilities, hospitals, and others.

The unit dose manufacturing research report is one of a series of new reports that provides unit dose manufacturing market statistics, including the unit dose manufacturing industry's global market size, regional shares, competitors with unit dose manufacturing market share, detailed unit dose manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the unit dose manufacturing industry. This unit dose manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The unit dose manufacturing market consists of sales of sachets, small bottles, tubes, and pods. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.